Featured Publications
Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines
Adamkiewicz T, Yee M, Thomas S, Tunali A, Lai K, Omole F, Lane P, Yildirim I. Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines. Blood Advances 2023, 7: 6751-6761. PMID: 37698500, PMCID: PMC10660014, DOI: 10.1182/bloodadvances.2022009643.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseSickle cell diseaseCell diseasePCV13-serotype invasive pneumococcal diseaseSerotype invasive pneumococcal diseaseNon-PCV13 serotypesPneumococcal polysaccharide vaccinePneumococcal conjugate vaccineIncidence rate ratiosYears of vaccinationReference populationLife-threatening risksIPD episodesIPD serotypesPneumococcal diseasePneumococcal infectionPolysaccharide vaccineConjugate vaccineHemoglobin SSVaccine licensureEffective vaccinePenicillin resistanceDisease controlVaccineAfrican American children
2024
Leveraging real-world Data from administrative claims and medical records to inform safety and effectiveness of piperacillin-tazobactam in the Management of Pediatric Hospital Acquired Pneumonia
Blumenstock J, Faerber J, Menon M, Lawler R, Downes K, Kratz E, Erickson K, Haltzman-Cassenti B, Yildirim I, Hussaini L, Elmontser M, Sederdahl B, Hahn A, Thomson J, Newland J, Terrill C, Bradley J, Zachariah P, Younus M, Mo J, Wible M, Tawadrous M, Fisher B. Leveraging real-world Data from administrative claims and medical records to inform safety and effectiveness of piperacillin-tazobactam in the Management of Pediatric Hospital Acquired Pneumonia. American Journal Of Epidemiology 2024, kwae251. PMID: 39108170, DOI: 10.1093/aje/kwae251.Peer-Reviewed Original ResearchIncidence rate ratiosPediatric Health Information SystemHospital-acquired pneumoniaMedical recordsHealth information systemsPoisson regression modelsBetween-group differencesStudy combined dataEffects of medicationAdministrative claimsRate ratiosClinical improvementSecondary outcomesBetween-groupEffect of piperacillin-tazobactamComparative riskReal World DataHospital acquired pneumoniaRegression modelsTreating hospital-acquired pneumoniaOff-label settingCIPediatric institutionControlled studiesPiperacillin-tazobactam
2021
Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
Bennett JC, Hetrich MK, Garcia Quesada M, Sinkevitch JN, Deloria Knoll M, Feikin DR, Zeger SL, Kagucia EW, Cohen AL, Ampofo K, Brandileone MC, Bruden D, Camilli R, Castilla J, Chan G, Cook H, Cornick JE, Dagan R, Dalby T, Danis K, de Miguel S, De Wals P, Desmet S, Georgakopoulou T, Gilkison C, Grgic-Vitek M, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kellner JD, Kleynhans J, Knol MJ, Kozakova J, Kristinsson KG, Ladhani SN, MacDonald L, Mackenzie GA, Mad’arová L, McGeer A, Mereckiene J, Morfeldt E, Mungun T, Muñoz-Almagro C, Nuorti JP, Paragi M, Pilishvili T, Puentes R, Saha SK, Sahu Khan A, Savrasova L, Scott JA, Skoczyńska A, Suga S, van der Linden M, Verani JR, von Gottberg A, Winje BA, Yildirim I, Zerouali K, Hayford K, . Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project. Microorganisms 2021, 9: 696. PMID: 33801760, PMCID: PMC8066231, DOI: 10.3390/microorganisms9040696.Peer-Reviewed Original ResearchInvasive pneumococcal diseasePneumococcal conjugate vaccinePneumococcal diseaseIncidence rateSerotype 1Streptococcus pneumoniae serotype 1Mixed-effects Poisson regressionInfant immunization programIntroduction of PCV10Pneumococcal serotype replacementIncidence rate ratiosIPD surveillance dataYears of ageIPD incidenceSerotype replacementLinear mixed-effects regressionConjugate vaccineBurden countriesImmunization programsMixed-effects regressionImportant causePoisson regressionSurveillance dataRate ratioPCV10/13
2020
Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
Lapidot R, Shea KM, Yildirim I, Cabral HJ, Pelton SI, Health T. Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts. Pathogens 2020, 9: 396. PMID: 32455770, PMCID: PMC7281000, DOI: 10.3390/pathogens9050396.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineIPD casesIncidence rate ratiosIPD incidencePCV-13Disease characteristicsSerotype 3 invasive pneumococcal diseaseInvasive pneumococcal disease incidenceImpact of PCV13Presence of comorbiditiesInvasive pneumococcal diseasePneumococcal disease incidenceUniversal childhood immunizationWaning of immunityPassive surveillance systemPCV13 dosePCV13 introductionVaccine effectivenessConjugate vaccineMassachusetts childrenPneumococcal diseaseClinical syndromeChildhood immunizationIncidence ratePCV13